(Q45259654)

English

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

scientific article published in April 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Marin D

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Kaeda J

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Saunders S

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Fleming A

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Howard J

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Andreasson C

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Bua M

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Olavarria E

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Rahemtulla A

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dazzi F

11

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Kanfer E

12

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Goldman JM

13

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Apperley JF

14

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

507-512

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Identifiers

10.1038/SJ.LEU.2403664

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45259654&oldid=2207178182"